Q32 Bio Inc. QTTB
9.30 USD +0.45 (+5.11%)
Nov 6, 2026, 11:01 AM EST
8.97 Day range 9.31
1.91 52-week range 23.57
- YTD
- +180.20%
- 1 year
- +300.97%
Analyst view
Consensus: buy
Buy
Price target (mean) 17.40 +87.0% upside
Now 9.30
- Target (low)
- 9.00
- Target (mean)
- 17.40
- Target (high)
- 22.00
Ratings (0m) 5 3 buy · 2 hold · 0 sell
- Strong buy2
- Buy1
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 6
- 2 months ago 6
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Dec 12, 2024 | Guggenheim | Downgrade | Buy | Neutral |
| Dec 11, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Dec 11, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Dec 11, 2024 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Dec 11, 2024 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Dec 11, 2024 | Raymond James | Downgrade | Strong Buy | Outperform |
| Dec 6, 2024 | BMO Capital | Initiated | — | Outperform |
| Oct 24, 2024 | Raymond James | Initiated | — | Strong Buy |
| Sep 11, 2024 | Wells Fargo | Initiated | — | Overweight |
| Jun 17, 2024 | Guggenheim | Initiated | — | Buy |
| May 21, 2024 | Leerink Partners | Initiated | — | Outperform |
| Apr 11, 2024 | Oppenheimer | Initiated | — | Outperform |
| Apr 2, 2024 | Piper Sandler | Initiated | — | Overweight |